Inhibiting the type 2 inflammatory pathway with dupilumab is associated with an increase in interleukin ‐4 and interleukin‐18 production

Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Tags: RESEARCH NOTE Source Type: research